Five Prime Therapeutics (FPRX) Tops Q1 EPS by 4c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q1 EPS of ($1.02), $0.04 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $5.35 million versus the consensus estimate of $4.79 million.

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c